Literature DB >> 16520743

Cannabinoid 1 (CB1) receptors coupled to cholinergic motorneurones inhibit neurogenic circular muscle contractility in the human colon.

Nicholas M Hinds1, Katja Ullrich, Scott D Smid.   

Abstract

The effects of cannabinoid subtype 1 (CB(1)) receptor activation were determined on smooth muscle, inhibitory and excitatory motorneuronal function in strips of human colonic longitudinal muscle (LM) and circular muscle (CM) in vitro. Electrical field stimulation (EFS; 0.5-20 Hz, 50 V) evoked a relaxation in LM and CM precontracted with a neurokinin-2 (NK-2) selective receptor agonist (beta-ala(8)-neurokinin A; 10(-6) M) in the presence of atropine (10(-6) M); this was unaltered following pretreatment with the CB(1)-receptor selective agonist arachidonyl-2-chloroethylamide (ACEA; 10(-6) M). In the presence of nitric oxide synthase blockade with N-nitro-L-arginine (10(-4) M), EFS evoked a frequency-dependent 'on-contraction' during stimulation and an 'off-contraction' following stimulus cessation. On-contractions were significantly inhibited in CM strips by pretreatment with ACEA (10(-6) M). These inhibitory effects were reversed in the presence of the CB(1) receptor-selective antagonist N-(piperidine-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (10(-7) M). ACEA did not alter LM or CM contractile responses to acetylcholine or NK-2 receptor-evoked contraction. Immunohistochemical studies revealed a colocalisation of CB(1) receptors to cholinergic neurones in the human colon based on colabelling with choline acetyltransferase, in addition to CB(1) receptor labelling in unidentified structures in the CM. In conclusion, activation of CB(1) receptors coupled to cholinergic motorneurones selectively and reversibly inhibits excitatory nerve transmission in colonic human colonic CM. These results provide evidence of a direct role for cannabinoids in the modulation of motor activity in the human colon by coupling to cholinergic motorneurones.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16520743      PMCID: PMC1617060          DOI: 10.1038/sj.bjp.0706710

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  47 in total

1.  Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus.

Authors:  Angela A Coutts; Andrew J Irving; Ken Mackie; Roger G Pertwee; Sharon Anavi-Goffer
Journal:  J Comp Neurol       Date:  2002-07-08       Impact factor: 3.215

2.  Cholinergic and nitrergic interneurones in the myenteric plexus of the human colon.

Authors:  A J Porter; D A Wattchow; S J H Brookes; M Costa
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 3.  Evolving concepts in functional gastrointestinal disorders: promising directions for novel pharmaceutical treatments.

Authors:  Richard H Hunt; Gervais Tougas
Journal:  Best Pract Res Clin Gastroenterol       Date:  2002-12       Impact factor: 3.043

4.  Nitric oxide is involved in the relaxant effect of capsaicin in the human sigmoid colon circular muscle.

Authors:  L Barthó; R Benkó; Z Lázár; L Illényi; O P Horváth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2002-09-11       Impact factor: 3.000

5.  Endocannabinoids as physiological regulators of colonic propulsion in mice.

Authors:  Luisa Pinto; Angelo A Izzo; Maria Grazia Cascio; Tiziana Bisogno; Karen Hospodar-Scott; David R Brown; Nicola Mascolo; Vincenzo Di Marzo; Francesco Capasso
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

6.  Possible endocannabinoid control of colorectal cancer growth.

Authors:  Alessia Ligresti; Tiziana Bisogno; Isabel Matias; Luciano De Petrocellis; Maria Grazia Cascio; Vittorio Cosenza; Giuseppe D'argenio; Giuseppe Scaglione; Maurizio Bifulco; Italo Sorrentini; Vincenzo Di Marzo
Journal:  Gastroenterology       Date:  2003-09       Impact factor: 22.682

7.  Acidic nonsteroidal anti-inflammatory drugs inhibit rat brain fatty acid amide hydrolase in a pH-dependent manner.

Authors:  Christopher J Fowler; Sandra Holt; Gunnar Tiger
Journal:  J Enzyme Inhib Med Chem       Date:  2003-02       Impact factor: 5.051

8.  Downregulation of class II transactivator (CIITA) expression by synthetic cannabinoid CP55,940.

Authors:  Celine Gongora; Stacey Hose; Terrence P O'Brien; Debasish Sinha
Journal:  Immunol Lett       Date:  2004-01-30       Impact factor: 3.685

Review 9.  Cannabinoids for gastrointestinal diseases: potential therapeutic applications.

Authors:  Giulia Di Carlo; Angelo A Izzo
Journal:  Expert Opin Investig Drugs       Date:  2003-01       Impact factor: 6.206

10.  Differential distribution of functional cannabinoid CB1 receptors in the mouse gastroenteric tract.

Authors:  Maria Antonietta Casu; Anna Porcella; Stefania Ruiu; Pierluigi Saba; Giorgio Marchese; Mauro Antonio Maria Carai; Roberta Reali; Gian Luigi Gessa; Luca Pani
Journal:  Eur J Pharmacol       Date:  2003-01-10       Impact factor: 4.432

View more
  17 in total

1.  Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea.

Authors:  B S Wong; M Camilleri; D Eckert; P Carlson; M Ryks; D Burton; A R Zinsmeister
Journal:  Neurogastroenterol Motil       Date:  2012-01-30       Impact factor: 3.598

2.  Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome.

Authors:  Banny S Wong; Michael Camilleri; Irene Busciglio; Paula Carlson; Lawrence A Szarka; Duane Burton; Alan R Zinsmeister
Journal:  Gastroenterology       Date:  2011-07-29       Impact factor: 22.682

3.  Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice.

Authors:  M A Storr; M Bashashati; C Hirota; V K Vemuri; C M Keenan; M Duncan; B Lutz; K Mackie; A Makriyannis; W K Macnaughton; K A Sharkey
Journal:  Neurogastroenterol Motil       Date:  2010-02-24       Impact factor: 3.598

Review 4.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 5.  Cannabinoid hyperemesis syndrome.

Authors:  Jonathan A Galli; Ronald Andari Sawaya; Frank K Friedenberg
Journal:  Curr Drug Abuse Rev       Date:  2011-12

6.  Systemic Injections of Cannabidiol Enhance Acetylcholine Levels from Basal Forebrain in Rats.

Authors:  Eric Murillo-Rodríguez; Gloria Arankowsky-Sandoval; Nuno Barbosa Rocha; Rodrigo Peniche-Amante; André Barciela Veras; Sérgio Machado; Henning Budde
Journal:  Neurochem Res       Date:  2018-06-06       Impact factor: 3.996

Review 7.  Endocannabinoids and the gastrointestinal tract: what are the key questions?

Authors:  G J Sanger
Journal:  Br J Pharmacol       Date:  2007-09-03       Impact factor: 8.739

8.  Cannabinoids inhibit cholinergic contraction in human airways through prejunctional CB1 receptors.

Authors:  S Grassin-Delyle; E Naline; A Buenestado; C Faisy; J-C Alvarez; H Salvator; C Abrial; C Advenier; L Zemoura; P Devillier
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

9.  Effects of excitatory and inhibitory neurotransmission on motor patterns of human sigmoid colon in vitro.

Authors:  M Aulí; E Martínez; D Gallego; A Opazo; F Espín; M Martí-Gallostra; M Jiménez; P Clavé
Journal:  Br J Pharmacol       Date:  2008-09-01       Impact factor: 8.739

10.  The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high-fat diet.

Authors:  V Di Marzo; R Capasso; I Matias; G Aviello; S Petrosino; F Borrelli; B Romano; P Orlando; F Capasso; A A Izzo
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.